B
Bull
Bull · 25%NBTX
$5.75
Scenario price
$24.140
+3.505 (+14.52%)At close
Loading chart…
- High
- 24.510
- Open
- 21.450
- VWAP
- 23.37
- Volume
- 137.90K
- Mkt Cap
- 263.82M
- Low
- 21.450
- Amount
- 3.22M
- EV/EBITDA, TTM
- -7.64
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
AI analysis of Nanobiotix SA (NBTX)
HoldWhile Nanobiotix SA (NBTX) has potential for long-term growth, current indicators suggest it may not be the best buy right now. The stock's RSI is at a low 22.236, indicating it is oversold, but the forward P/E ratio is high at 42.3729, suggesting it may be overvalued compared to earnings expectations. Additionally, insider activity is neutral, and hedge funds have increased selling by 1048.78% in the last quarter, which raises concerns about market sentiment. The stock has seen a 5-day change of -10.05% and a 20-day change of -35.55%, indicating significant downward pressure. Therefore, it may be prudent to hold off on purchasing until there are clearer signs of recovery or stabilization in the stock's performance.
Valuation Metrics
The current forward P/E ratio for Nanobiotix SA (NBTX) is 42.37, compared to its 5-year average forward P/E of 12.24.
Alphio AI Price Scenarios for NBTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NBTX
Events Timeline
News
8.508-31FoolJohnson & Johnson's Investment Portfolio Reveals Biotech Potential
8.508-25NewsfilterNanobiotix Updates on Voting Rights and Shares
8.507-30GlobenewswireNanobiotix Updates Shareholder Voting Rights Information
9.506-03NASDAQ.COMNanobiotix Reports Q1 2026 Financial and Operational Update
- 8.506-02Newsfilter
Nanobiotix Completes €86.1 Million Follow-On Offering
NBTX FAQ — answered by Alphio AI
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo. It operates in the Healthcare sector.
While Nanobiotix SA (NBTX) has potential for long-term growth, current indicators suggest it may not be the best buy right now. The stock's RSI is at a low 22.236, indicating it is oversold, but the forward P/E ratio is high at 42.3729, suggesting it may be overvalued compared to earnings expectations. Additionally, insider activity is neutral, and hedge funds have increased selling by 1048.78% in the last quarter, which raises concerns about market sentiment. The stock has seen a 5-day change of -10.05% and a 20-day change of -35.55%, indicating significant downward pressure. Therefore, it may be prudent to hold off on purchasing until there are clearer signs of recovery or stabilization in the stock's performance.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.